Adrian Haigh Exits as COO of Fennec Pharmaceuticals
Company Announcements

Adrian Haigh Exits as COO of Fennec Pharmaceuticals

Fennec Pharmaceuticals (FRX) has provided an update.

Adrian Haigh has stepped down as Chief Operating Officer of Fennec Pharmaceuticals Inc., after transitioning to the role in August 2023 and serving as an independent director for nine years. In line with his departure, Haigh and the company have agreed to a Confidential Separation Agreement, which includes the acceleration of options vesting for Haigh to purchase company shares at a set price before they expire in mid-2027.

See more data about FRX stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskFennec Pharmaceuticals Reports Q3 2024 Financial Results
TheFlyFennec price target lowered to $15 from $22 at Maxim
TheFlyFennec reports Q3 EPS (21c), consensus (9c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App